A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7-valent Pneumococcal Conjugate Vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 41 sites in Spain. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-16.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccinations in Spain.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Biological: 7-valent Pneumococcal Conjugate Vaccine
Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or \>=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.
Time frame: One month after 2-doses of the infant series (5 months of age)
Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Time frame: One month after 2-doses of the infant series (5 months of age)
Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Time frame: One month after 2-doses of the infant series (5 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[Decr\] appetite, irritability, increased \[Incr\] sleep, decreased sleep, hives, use of medication \[Med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.
Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.
Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Participants were recruited in Spain from October 2006 to December 2006.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 315 | 304 |
| Vaccinated dose 1 | 314 | 302 |
| Vaccinated dose 2 | 307 | 298 |
| Vaccinated dose 3 | 301 | 296 |
| Completed | 299 | 294 |
| Not completed | 16 | 10 |
| Withdrew: Withdrawal by subject | 11 | 6 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Randomization error | 0 | 1 |
| Withdrew: Failed to meet eligibility criteria | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Failed to return | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 299 | 294 |
| Completed | 293 | 289 |
| Not completed | 6 | 5 |
| Withdrew: Failed to return | 3 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 293 | 289 |
| Completed | 292 | 286 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or \>=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.
| Percentage of Participants | 13vPnC | 7vPnC |
|---|---|---|
| Meningococcal C ≥ 1:8 | 98.3 (96.1 to 99.5) | 98.9 (96.9 to 99.8) |
| Diptheria ≥ 0.10 IU/mL | 95.9 (93.0 to 97.9) | 94.7 (91.4 to 97.0) |
| Diptheria ≥ 0.01 IU/mL | 100.0 (98.8 to 100.0) | 100.0 (98.7 to 100.0) |
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series | 191.22 (167.72 to 218.02) | 266.19 (234.86 to 301.71) |
| IU/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series | 0.51 (0.47 to 0.57) | 0.63 (0.57 to 0.70) |
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=275,270,227,232,217,215,193,170) | 49.5 | 43.3 | 45.4 | 46.6 | 47.9 | 41.9 | 64.2 | 64.7 |
| Tenderness-Sig (n=247,250,192,203,181,171,136,118 | 2.8 | 2.8 | 4.2 | 3.9 | 6.1 | 0.0 | 5.9 | 6.8 |
| Swelling-Any (n=252,254,206,212,203,181,153,140) | 19.0 | 14.2 | 28.2 | 23.1 | 27.6 | 28.2 | 33.3 | 30.7 |
| Swelling-Mild (n=251,254,206,212,201,186,151,132) | 16.3 | 14.2 | 25.7 | 20.3 | 26.4 | 25.8 | 31.1 | 24.2 |
| Swelling-Mod (n=247,248,191,201,180,173,136,124) | 4.9 | 1.6 | 5.8 | 4.5 | 5.6 | 4.0 | 11.8 | 12.9 |
| Swelling-Severe(n=246,247,191,201,176,171,131,113) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=255,251,211,217,203,198,159,146) | 22.0 | 19.1 | 34.1 | 30.9 | 31.0 | 34.8 | 40.9 | 41.1 |
| Redness-Mild (n=254,251,210,215,203,195,157,141) | 20.1 | 18.3 | 32.4 | 30.2 | 29.1 | 33.3 | 35.0 | 37.6 |
| Redness-Mod (n=247,247,192,203,177,175,137,120) | 2.4 | 1.2 | 3.1 | 2.5 | 4.5 | 5.1 | 13.1 | 12.5 |
| Redness-Severe (n=246,247,191,201,176,171,131,113) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[Decr\] appetite, irritability, increased \[Incr\] sleep, decreased sleep, hives, use of medication \[Med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Fv≥38°C, ≤39°C (n=262,253,213,223,198,196,162,145) | 30.5 | 24.5 | 40.4 | 41.7 | 34.3 | 38.3 | 38.9 | 44.8 |
| Fv>39°C, ≤40°C (n=249,247,194,204,177,174,135,118) | 0.8 | 0.8 | 2.6 | 2.5 | 5.6 | 5.2 | 8.1 | 6.8 |
| Fv >40°C (n=249,247,192,201,176,171,132,113) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 |
| Decr appetite (n=269,258,226,229,219,204,174,147) | 39.8 | 36.8 | 45.1 | 44.5 | 47.0 | 42.6 | 53.4 | 47.6 |
| Irritability (n=276,267,234,244,229,221,183,170) | 51.4 | 42.7 | 64.5 | 61.5 | 57.2 | 58.8 | 61.7 | 61.8 |
| Incr sleep (n=273,269,218,221,206,203,160,145) | 53.5 | 51.3 | 46.8 | 41.6 | 33.5 | 34.5 | 39.4 | 35.2 |
| Decr sleep (n=263,255,218,223,205,190,151,129) | 34.6 | 24.7 | 36.2 | 29.6 | 30.2 | 25.8 | 27.2 | 27.1 |
| Med-treat sx (n=267,256,232,243,216,209,176,163) | 50.6 | 46.9 | 60.3 | 61.3 | 55.6 | 55.5 | 59.7 | 60.1 |
| Med-prevent sx (n=269,258,231,237,222,211,178,159) | 49.1 | 47.7 | 58.4 | 58.6 | 56.3 | 53.6 | 59.6 | 61.6 |
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC After Infant Series Dose 2 | 13vPnC After Infant Series Dose 3 | 13vPnC After the Toddler Dose |
|---|---|---|---|
| Common Serotype - Serotype 4 (n=269,269,241) | 1.89 (1.70 to 2.10) | 2.33 (2.11 to 2.57) | 4.97 (4.42 to 5.58) |
| Common Serotype - Serotype 6B (n=267,267,228) | 0.42 (0.37 to 0.47) | 3.88 (3.41 to 4.41) | 11.88 (10.57 to 13.35) |
| Common Serotype - Serotype 9V (n=273,273,241) | 1.49 (1.34 to 1.66) | 1.71 (1.56 to 1.86) | 3.44 (3.12 to 3.80) |
| Common Serotype - Serotype 14 (n=270,270,230) | 3.84 (3.37 to 4.37) | 6.17 (5.45 to 6.98) | 11.37 (10.17 to 12.71) |
| Common Serotype - Serotype 18C (n=267,267,239) | 1.58 (1.40 to 1.78) | 2.29 (2.08 to 2.52) | 3.96 (3.55 to 4.43) |
| Common Serotype - Serotype 19F (n=270,270,231) | 2.85 (2.53 to 3.21) | 2.64 (2.42 to 2.89) | 8.04 (7.07 to 9.14) |
| Common Serotype - Serotype 23F (n=260,260,233) | 0.54 (0.47 to 0.62) | 2.15 (1.89 to 2.45) | 5.07 (4.50 to 5.71) |
| Additional Serotype - Serotype 1 (n=268,268,235) | 1.90 (1.70 to 2.13) | 3.04 (2.73 to 3.38) | 4.79 (4.21 to 5.45) |
| Additional Serotype - Serotype 3 (n=267,267,243) | 0.79 (0.72 to 0.87) | 0.97 (0.87 to 1.08) | 1.07 (0.95 to 1.20) |
| Additional Serotype - Serotype 5 (n=261,261,234) | 0.99 (0.90 to 1.10) | 1.93 (1.74 to 2.13) | 3.90 (3.53 to 4.31) |
| Additional Serotype - Serotype 6A (n=269,269,235) | 1.10 (0.97 to 1.25) | 3.16 (2.82 to 3.53) | 7.07 (6.35 to 7.87) |
| Additional Serotype - Serotype 7F (n=268,268,242) | 1.85 (1.69 to 2.02) | 4.03 (3.70 to 4.40) | 5.78 (5.13 to 6.53) |
| Additional Serotype - Serotype 19A (n=267,267,226) | 2.36 (2.10 to 2.66) | 3.07 (2.79 to 3.37) | 11.64 (10.43 to 13.00) |
Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.
| percentage of participants | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Pertussis, PT ≥ 5.0 EU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 99.6 (98.0 to 100.0) | 99.6 (97.9 to 100.0) |
| Pertussis, PT (Infant ≥ 20; Toddler ≥ 11) EU/mL | 93.2 (89.7 to 95.8) | 95.1 (91.9 to 97.3) | 94.9 (91.6 to 97.2) | 96.3 (93.3 to 98.2) |
| Pertussis, FHA ≥ 5.0 EU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) |
| Pertussis, FHA ≥ 7.82 EU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) |
| Pertussis, FHA (Infant ≥ 64; Toddler ≥ 99) EU/mL | 93.9 (90.5 to 96.3) | 95.1 (91.9 to 97.3) | 94.5 (91.1 to 96.9) | 95.1 (91.8 to 97.4) |
| Pertussis, PRN ≥ 5 EU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) |
| Pertussis, PRN (Infant ≥ 39; Toddler ≥ 69) EU/mL | 94.5 (91.3 to 96.8) | 95.1 (91.9 to 97.3) | 93.5 (89.9 to 96.1) | 95.2 (91.9 to 97.4) |
| Diptheria ≥ 0.10 IU/mL | 99.3 (97.5 to 99.9) | 100.0 (98.7 to 100.0) | 99.2 (97.2 to 99.9) | 100.0 (98.5 to 100.0) |
| Diptheria ≥ 0.01 IU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) |
| Tetanus ≥ 0.10 IU/mL | 98.6 (96.3 to 99.6) | 98.2 (95.8 to 99.4) | 98.6 (95.9 to 99.7) | 97.8 (94.9 to 99.3) |
| Tetanus ≥ 0.01 IU/mL | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.3 to 100.0) | 100.0 (98.4 to 100.0) |
| Poliovirus, Type 1 ≥ 1:8 | 100.0 (98.7 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) |
| Poliovirus, Type 2 ≥ 1:8 | 100.0 (98.7 to 100.0) | 99.3 (97.5 to 99.9) | 100.0 (98.6 to 100.0) | 99.6 (97.8 to 100.0) |
| Poliovirus, Type 3 ≥ 1:8 | 100.0 (98.7 to 100.0) | 99.6 (98.0 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) |
| titer | 13vPnC After Infant Series Dose 3 | 7vPnC After Infant Series Dose 3 | 13vPnC After the Toddler Dose | 7vPnC Afte the Toddler Dose |
|---|---|---|---|---|
| Poliovirus Type 1 | 436.98 (378.21 to 504.88) | 436.15 (378.17 to 503.02) | 1057.40 (939.06 to 1190.70) | 1286.70 (1131.00 to 1463.80) |
| Poliovirus Type 2 | 266.34 (227.84 to 311.36) | 281.85 (240.04 to 330.94) | 1032.30 (912.96 to 1167.10) | 1141.10 (992.96 to 1311.40) |
| Poliovirus Type 3 | 897.67 (766.30 to 1051.60) | 943.95 (806.71 to 1104.50) | 2571.10 (2249.40 to 2938.90) | 2410.80 (2106.70 to 2758.80) |
| IU/mL | 13vPnC After Infant Series Dose 3 | 7vPnC After Infant Series Dose 3 | 13vPnC After the Toddler Dose | 7vPnC Afte the Toddler Dose |
|---|---|---|---|---|
| Diphtheria | 1.19 (1.08 to 1.30) | 1.40 (1.28 to 1.53) | 3.00 (2.65 to 3.40) | 3.51 (3.08 to 3.99) |
| Tetanus | 0.90 (0.80 to 1.01) | 0.87 (0.79 to 0.97) | 1.63 (1.38 to 1.91) | 1.45 (1.24 to 1.69) |
GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.
| EU/mL | 13vPnC After Infant Series Dose 3 | 7vPnC After Infant Series Dose 3 | 13vPnC After the Toddler Dose | 7vPnC Afte the Toddler Dose |
|---|---|---|---|---|
| Pertussis PT | 51.51 (47.94 to 55.34) | 50.13 (46.80 to 53.70) | 36.13 (32.84 to 39.74) | 36.01 (32.94 to 39.37) |
| Pertussis FHA | 179.04 (165.34 to 193.87) | 166.77 (155.20 to 179.20) | 347.96 (316.46 to 382.59) | 345.89 (315.14 to 379.65) |
| Pertussis PRN | 141.39 (129.66 to 154.17) | 135.06 (123.56 to 147.63) | 232.96 (211.42 to 256.69) | 261.58 (237.29 to 288.36) |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of Participants | 13vPnC After Infant Series Dose 2 | 13vPnC After Infant Series Dose 3 | 13vPnC After the Toddler Dose |
|---|---|---|---|
| Common Serotype - Serotype 4 | 96.7 (93.7 to 98.5) | 98.9 (96.8 to 99.8) | 99.2 (97.0 to 99.9) |
| Common Serotype - Serotype 6B | 57.3 (51.1 to 63.3) | 98.5 (96.2 to 99.6) | 99.6 (97.6 to 100.0) |
| Common Serotype - Serotype 9V | 91.9 (88.1 to 94.9) | 99.3 (97.4 to 99.9) | 100.0 (98.5 to 100.0) |
| Common Serotype - Serotype 14 | 98.5 (96.3 to 99.6) | 97.4 (94.7 to 99.0) | 100.0 (98.4 to 100.0) |
| Common Serotype - Serotype 18C | 91.8 (87.8 to 94.8) | 98.1 (95.7 to 99.4) | 99.6 (97.7 to 100.0) |
| Common Serotype - Serotype 19F | 97.8 (95.2 to 99.2) | 99.3 (97.3 to 99.9) | 99.6 (97.6 to 100.0) |
| Common Serotype - Serotype 23F | 68.1 (62.0 to 73.7) | 94.6 (91.1 to 97.0) | 99.1 (96.9 to 99.9) |
| Additional Serotype - Serotype 1 | 96.3 (93.2 to 98.2) | 99.3 (97.3 to 99.9) | 98.7 (96.3 to 99.7) |
| Additional Serotype - Serotype 3 | 88.0 (83.5 to 91.7) | 90.3 (86.1 to 93.5) | 92.2 (88.1 to 95.2) |
| Additional Serotype - Serotype 5 | 87.4 (82.7 to 91.1) | 97.3 (94.6 to 98.9) | 99.1 (96.9 to 99.9) |
| Additional Serotype - Serotype 6A | 84.4 (79.5 to 88.5) | 97.4 (94.7 to 98.9) | 99.1 (97.0 to 99.9) |
| Additional Serotype - Serotype 7F | 98.5 (96.2 to 99.6) | 100.0 (98.6 to 100.0) | 98.8 (96.4 to 99.7) |
| Additional Serotype - Serotype 19A | 98.1 (95.7 to 99.4) | 99.6 (97.9 to 100.0) | 100.0 (98.4 to 100.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 16/314 (5.1%) | 151/314 (48.1%) |
| 7vPnC Infant Series | — | 16/300 (5.3%) | 156/300 (52%) |
| 13vPnC Post-Infant Series | — | 16/314 (5.1%) | 7/314 (2.2%) |
| 7vPnC Post-Infant Series | — | 16/300 (5.3%) | 10/300 (3.3%) |
| 13vPnC Toddler Series | — | 3/291 (1%) | 124/291 (42.6%) |
| 7vPnC Toddler Series | — | 1/284 (0.4%) | 110/284 (38.7%) |
| 13vPnC 6-Month Follow-up | — | 3/312 (1%) | 3/312 (1%) |
| 7vPnC 6-Month Follow-up | — | 6/299 (2%) | 2/299 (0.7%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| Induration (Moderate)Skin and subcutaneous tissue disorders | 12/247 | 4/248 | 16/136 | 16/124 | — | — | — | — |
| BronchiolitisInfections and infestations | 6/314 | 6/300 | 0/314 | 0/300 | 0/291 | 0/284 | 0/312 | 0/299 |
| Urinary tract infectionInfections and infestations | 0/314 | 4/300 | 1/314 | 0/300 | 0/291 | 0/284 | 0/312 | 0/299 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 4/314 | 1/300 | 0/314 | 1/300 | 0/291 | 0/284 | 0/312 | 0/299 |
| Febrile convulsionNervous system disorders | 0/314 | 1/300 | 1/314 | 1/300 | 0/291 | 0/284 | 0/312 | 2/299 |
| BronchitisInfections and infestations | 2/314 | 1/300 | 1/314 | 2/300 | 0/291 | 0/284 | 0/312 | 1/299 |
| GastroenteritisGastrointestinal disorders | 1/314 | 2/300 | 0/314 | 1/300 | 0/291 | 0/284 | 2/312 | 0/299 |
| PyrexiaGeneral disorders | 1/314 | 2/300 | 0/314 | 0/300 | 0/291 | 0/284 | 0/312 | 1/299 |
| Gastroenteritis rotavirusGastrointestinal disorders | 0/314 | 0/300 | 2/314 | 0/300 | 1/291 | 0/284 | 0/312 | 1/299 |
| Arthritis bacterialInfections and infestations | 0/314 | 0/300 | 0/314 | 0/300 | 0/291 | 1/284 | 0/312 | 0/299 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| Tenderness (Any)Skin and subcutaneous tissue disorders | 136/275 | 117/270 | — | — | 124/193 | 110/170 | — | — |
| IrritabilityGeneral disorders | 151/234 | 150/244 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 142/276 | 114/267 | — | — | 113/183 | 105/170 | — | — |
| IrritabilityGeneral disorders | 131/229 | 130/221 | — | — | — | — | — | — |
| Increased sleepGeneral disorders | 146/273 | 138/269 | — | — | 63/160 | 51/145 | — | — |
| Decreased appetiteGeneral disorders | 107/269 | 95/258 | — | — | 93/174 | 70/147 | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 104/217 | 90/215 | — | — | — | — | — | — |
| Decreased appetiteGeneral disorders | 103/219 | 87/204 | — | — | — | — | — | — |
| Increased sleepGeneral disorders | 102/218 | 92/221 | — | — | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 103/227 | 108/232 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.5 | 2.1 ± 0.5 | 2.1 ± 0.5 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 148 | 152 | 300 |
| Male | 167 | 152 | 319 |
The record gives a start of Oct 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years 1 month after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →